Searched for
ONCOLOGY DRUG DEVELOPMENT
Aragen Life Sciences begins operations at high-potency platform in HyderabadAragen Life Sciences has initiated operations at its new high-potency manufacturing platform in Hyderabad. The facility, measuring 15,000 s...- Could bacteria hold the secret to delaying death? Magnetic microbes extended worm lifespan by more than 43% in a new ageing studyResearchers at Hefei Institutes of Physical Science found that Magnetospirillum magneticum AMB-1 increased the lifespan of C. elegans by 43...
- Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil PatelZydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to f...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Ichor Biologics seeks $80-100 million PE funding for minority stake saleIchor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the...
- India’s chip push draws global interest; Quick comm's ad blitzIndia’s semiconductor push is gaining global attention as the country looks to build a stronger chip manufacturing ecosystem. This and more...
- ET Startup Awards 2026: Theranautilus’ nanorobots will be ready for human trials by year-endTheranautilus won the Top Innovator category at The Economic Times Startup Awards 2026 for its unique nanorobot technology, which is built ...
- ETSA winner Theranautilus heads to human trials; JSW One’s IPO plansHappy Friday! Theranautilus is set to begin human trials of its nanorobot-based dental tech soon. This and more in today’s ETtech Morning D...
- Dr. Reddy's launches nivolumab biosimilar in IndiaDr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- AstraZeneca's breast cancer drug fails in late-stage trialAstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement whe...
- Thinking long term and enduring volatility is the only way out: 5 mid-caps from different sectors with upside potential of up to 24%If you are an investor with some skin in the game, be ready to see some underperformance. Why? Because valuation readjustment can take more...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
- Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 croreFosun Pharma sold a 6% stake in Gland Pharma for ₹2,800 crore via a block deal, reducing its holding to 45.77%. Major buyers included Kotak...
- Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilarCipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s can...
- Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerGland Pharma shares fell 3% after 1.22 crore shares changed hands in two block deals worth nearly Rs 5,818 crore. Promoter Fosun Pharma Ind...
- Block deal alert! Gland Pharma shares fall 3% as 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerGland Pharma shares fell after a significant block deal involving Fosun Pharma Industrial. The company's VSEZ facility received zero USFDA ...
- Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impactSun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affor...
- Sun Pharma to extend MFN pricing to US state Medicaid programmesSun Pharma ranks second in US dermatology by prescriptions, with key brands including Ilumya for plaque psoriasis and Winlevi for acne. Rec...
Load More
